These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9750528)

  • 1. [Chemotherapy for hormone-refractory prostate cancer].
    Tsushima T
    Nihon Rinsho; 1998 Aug; 56(8):2167-72. PubMed ID: 9750528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of chemotherapy in prostate cancer. Minireview.
    Odrázka K; Vanásek J; Vaculíková M; Stejskal J; Filip S
    Neoplasma; 2000; 47(4):197-203. PubMed ID: 11043822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of systemic cytotoxic therapy for prostate cancer.
    Chang SS; Kibel AS
    BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic agents for hormone-refractory prostate cancer.
    Roth BJ
    Semin Oncol; 1996 Dec; 23(6 Suppl 14):49-55. PubMed ID: 8996586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of hormone refractory prostate cancer.
    Lin AM; Small EJ
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):187-91. PubMed ID: 18685361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy in advanced prostate cancer.
    Beedassy A; Cardi G
    Semin Oncol; 1999 Aug; 26(4):428-38. PubMed ID: 10482185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
    Ryan CJ; Lin AM; Small EJ
    Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.
    Shaw G; Oliver RT
    Surg Oncol; 2009 Sep; 18(3):275-82. PubMed ID: 19269165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
    Lin AM; Ryan CJ; Small EJ
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hormone refractory prostate cancer: current standards and future prospects.
    Oh WK; Kantoff PW
    J Urol; 1998 Oct; 160(4):1220-9. PubMed ID: 9751323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of Canadian trials in hormonally resistant prostate cancer.
    Moore MJ; Tannock IF
    Semin Oncol; 1996 Dec; 23(6 Suppl 14):15-9. PubMed ID: 8996579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    Vis AN; Schröder FH
    BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary hormonal therapy.
    Smith DC
    Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Other chemotherapy regimens including mitoxantrone and suramin.
    Siu LL; Moore MJ
    Semin Urol Oncol; 1997 Feb; 15(1):20-7. PubMed ID: 9050136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for the treatment of hormone-refractory prostate cancer.
    Chowdhury S; Burbridge S; Harper PG
    Int J Clin Pract; 2007 Dec; 61(12):2064-70. PubMed ID: 17956560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High-dose intravenous diethylstilbestrol diphosphate therapy for hormone refractory prostate cancer].
    Honda M; Umeda H; Yoshida K
    Nihon Rinsho; 1998 Aug; 56(8):2145-9. PubMed ID: 9750524
    [No Abstract]   [Full Text] [Related]  

  • 19. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
    Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
    Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
    Amin A; Halabi S; Gelmann EP; Stadler W; Vogelzang N; Small E
    Urol Oncol; 2004; 22(5):398-403. PubMed ID: 15464920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.